GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gain Therapeutics Inc (NAS:GANX) » Definitions » Marketable Securities

Gain Therapeutics (Gain Therapeutics) Marketable Securities : $2.02 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Gain Therapeutics Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Gain Therapeutics's Marketable Securities for the quarter that ended in Mar. 2024 was $2.02 Mil.

Gain Therapeutics's annual Marketable Securities increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($12.83 Mil) but then declined from Dec. 2022 ($12.83 Mil) to Dec. 2023 ($5.00 Mil).


Gain Therapeutics Marketable Securities Historical Data

The historical data trend for Gain Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gain Therapeutics Marketable Securities Chart

Gain Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Marketable Securities
Get a 7-Day Free Trial - - - 12.83 5.00

Gain Therapeutics Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.83 9.87 7.96 5.00 2.02

Gain Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Gain Therapeutics  (NAS:GANX) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".


Gain Therapeutics Marketable Securities Related Terms

Thank you for viewing the detailed overview of Gain Therapeutics's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Gain Therapeutics (Gain Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
4800 Montgomery Lane, Suite 220, Bethesda, MD, USA, 20814
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders and oncology. The company has filed four patent applications for novel small molecule drug candidates that are Structurally Targeted Allosteric Regulators (STARs). The company derives revenues from collaboration and licensing agreements.
Executives
Matthias Alder officer: Chief Operating Officer C/O MICROMET, INC., 6707 DEMOCRACY BLVD., STE. 505, BETHESDA MD 28017
Charles Evan Ballantyne officer: Chief Financial Officer 27 HEARTHSTONE ROAD, HOPKINTON MA 01748
Gianluca Fuggetta officer: Principal Accounting Officer C/O GAIN THERAPEUTICS, INC., 4800 MONTGOMERY LANE, SUITE 220, BETHESDA MD 20814
Eric I Richman director C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854
Salvatore Calabrese officer: Chief Financial Officer C/O GAIN THERAPEUTICS, INC., 4800 HAMPDEN LANE, SUITE 200, BETHESDA MD 20814
Hans Peter Hasler director C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Gwen A Melincoff director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Jeffrey Scott Riley director C/O ADEONA PHARMACEUTICALS, INC, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
Goldstein Dov A Md director
Khalid Islam director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Claude Nicaise director 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Manolo Bellotto officer: President and General Manager C/O GAIN THERAPEUTICS, INC., 4800 HAMPDEN LANE, SUITE 200, BETHESDA MD 20814

Gain Therapeutics (Gain Therapeutics) Headlines

From GuruFocus

Gain Therapeutics to Participate at the Jefferies Healthcare Conference

By GuruFocusNews GuruFocusNews 07-02-2022